Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival.

ABSTRACT:

Background

Patients treated with immune checkpoint inhibitors (ICIs) may experience pseudoprogression, which can be classified as progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1 and could lead to inappropriate treatment discontinuation. Immune-response criteria were developed to better capture novel response patterns seen with ICIs.

Methods

We pooled data from 1765 patients with 12 types of advanced solid tumors treated with avelumab (an anti-programmed death ligand 1 (PD-L1) monoclonal antibody) monotherapy in the JAVELIN Solid Tumor and JAVELIN Merkel 200 trials, conducted a comparative analysis of tumor assessments by investigators according to RECIST 1.1 and immune-related RECIST (irRECIST), and evaluated the correlation between pr

SUBMITTER: Manitz J 

PROVIDER: S-EPMC8886415 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature